<DOC>
	<DOCNO>NCT01803282</DOCNO>
	<brief_summary>This open-label , multicenter , sequential dose-escalation , expansion study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics andecaliximab ( formerly GS-5745 ) alone combination chemotherapy . The study consist 2 part ( Parts A B ) . Participants qualify participate 1 part . Part A sequential dose escalation determine maximum tolerate dose andecaliximab participant advance solid tumor refractory intolerant standard therapy standard therapy exist . In Part A , participant receive andecaliximab . Part A consist 12 48 participant . Part B dose expansion obtain additional safety tolerability data andecaliximab participant advance pancreatic adenocarcinoma , lung adenocarcinoma , lung squamous cell carcinoma , esophagogastric adenocarcinoma , colorectal cancer , breast cancer . In Part B , participant receive andecaliximab combination standard-of-care chemotherapy . Part B consist 115 295 participant . Please note study currently recruit breast cancer cohort .</brief_summary>
	<brief_title>Safety Tolerability Study Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Key Part A : histologically cytologically confirm advanced malignant solid tumor refractory intolerant standard therapy standard therapy available Part B : Pancreatic Adenocarcinoma Presence histologically confirm inoperable locally advanced metastatic pancreatic adenocarcinoma Part B : NSCLC Stage IIIB malignant pleural effusion/pleural seeding stage IV histologically confirm NSCLC Absence know epidermal growth factor receptor ( EGFR ) mutation Absence know translocation inversion event involve ALK gene locus ( result EML4ALK fusion ) Part B : Esophagogastric Adenocarcinoma : Histologically confirm inoperable advanced gastric adenocarcinoma ( include adenocarcinoma gastrooesophageal junction ) relapse gastric adenocarcinoma Human epidermal growth factor receptor 2 ( HER2 ) negative tumor ( primary tumor metastatic lesion ) Part B : FirstLine Colorectal Cancer Histologically confirm inoperable advanced adenocarcinoma colon rectum Radiographically measureable disease No prior cytotoxic chemotherapy treat metastatic disease Part B : SecondLine Colorectal Cancer Histologically confirm inoperable advanced adenocarcinoma colon rectum Radiographically measureable disease Received firstline combination therapy contain oxaliplatin fluoropyrimidine without bevacizumab metastatic disease document evidence disease progression treatment completion Part B : Breast Cancer Histologically cytologically confirm metastatic breast cancer Radiographically measureable disease Previous hormonal therapy metastatic breast cancer cytotoxic adjuvant chemotherapy allow Treatment weekly singleagent paclitaxel appropriate opinion treat physician HER2 negative tumor ( primary tumor metastatic lesion ) Adequate organ function Key Pregnant lactating Individuals know central nervous system ( CNS ) metastases , unless metastasis treat stable individual require systemic steroid Myocardial infarction , symptomatic congestive heart failure , unstable angina , serious uncontrolled cardiac arrhythmia within last 6 month Antitumor therapy within 28 day study drug dosing ; concurrent use hormone therapy breast prostate cancer permit Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Solid Tumor</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Pancreatic</keyword>
	<keyword>Esophagogastric</keyword>
	<keyword>Colorectal</keyword>
	<keyword>Breast</keyword>
</DOC>